<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828581</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-018</org_study_id>
    <nct_id>NCT00828581</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects</brief_title>
  <official_title>An Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the PK properties of lorcaserin in obese or
      overweight elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the single-dose pharmacokinetic (PK) parameters of lorcaserin in the obese or overweight Elderly (&gt; 65) to those obtained from the obese or overweight Adult (18-65)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of a single oral dose of lorcaserin in obese or overweight Elderly (&gt; 65) subjects and obese or overweight Adult (18-65) subjects.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorcaserin</intervention_name>
    <arm_group_label>Lorcaserin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females

          2. Control (Adult) group: aged between 18 and 65 years (inclusive)

          3. Elderly group: aged &gt; 65 years (includes subjects 1 day or more beyond the 65th
             birthday)

          4. Able to give signed informed consent

          5. BMI 27-45 kg/m2, inclusive 6. Eligible male and female subjects must agree not to
             participate in a conception process (i.e. active attempt to become pregnant or to
             impregnate, egg or sperm donation, in vitro fertilization).

          6. Considered to be in stable health in the opinion of the Investigator

        Exclusion Criteria:

          1. Prior participation in any study of lorcaserin.

          2. Clinically significant new illness in the 1 month before screening

          3. Not suitable to participate in the study in the opinion of the Investigator including
             an existing physical or mental condition that prevents compliance with the protocol

          4. History of any of the following cardiovascular conditions:

               -  Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG),
                  cerebral vascular accident (CVA), transient ischemic attack (TIA) or reversible
                  ischemic neurologic deficit (RIND) within 6 months of screening

               -  Cardiac arrhythmia requiring initiation of new medical or surgical treatment
                  within 6 months of screening (stable medical therapy for &gt; 6 months, pacemakers
                  and/or defibrillators implanted &gt; 6 months prior to screening are acceptable)

               -  Unstable angina

               -  History of pulmonary artery hypertension

          5. Positive result of HIV, hepatitis B or hepatitis C screens

          6. Initiation of a new prescription medication within 1 month prior to screening with the
             following exceptions:

          7. Use of SSRIs, SNRIs, and other medications must meet washout period.

          8. Participated in any clinical study with an investigational drug, biologic, or device
             within 1 month prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christen Anderson, MD, PhD</last_name>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI Worldwide - Lourdes Hospital</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>January 23, 2009</last_update_submitted>
  <last_update_submitted_qc>January 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christen Anderson, MD, PhD</name_title>
    <organization>Arena Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

